Toxicity (≥ G3) · people with cutaneous melanoma
BRAF inhibitors showed no clear difference in toxicity (≥ G3) compared with chemotherapy (low certainty).
1 finding from 1 review
RR 1.27 [0.48, 3.33]
408 participants
Low
Overall survival† · people with cutaneous melanoma
MEK inhibitors showed no clear difference in overall survival† compared with chemotherapy (low certainty).
1 finding from 1 review
HR 0.85 [0.58, 1.25]
496 participants
Low
Progression‐free survival · people with cutaneous melanoma
MEK inhibitors probably leads to lower progression‐free survival† compared with chemotherapy (moderate certainty).
1 finding from 1 review
HR 0.58 [0.42, 0.8]
496 participants
Moderate
Tumour response · people with cutaneous melanoma
MEK inhibitors leads to higher tumour response compared with chemotherapy (high certainty).
1 finding from 1 review
RR 2.01 [1.35, 2.99]
496 participants
High
Toxicity (≥ G3) · people with cutaneous melanoma
MEK inhibitors probably leads to higher toxicity (≥ G3) compared with chemotherapy (moderate certainty).
1 finding from 1 review
RR 1.61 [1.08, 2.41]
91 participants
Moderate
Tumour response · people with cutaneous melanoma
Anti‐PD1 monoclonal antibodies leads to higher tumour response compared with chemotherapy (high certainty).
1 finding from 1 review
RR 3.42 [2.38, 4.92]
1367 participants
High
Toxicity (≥ G3) · people with cutaneous melanoma
1 finding from 1 review
0.55 [0.31, 0.97]
1360 participants
Low
Disease-free survival · Patients treated with curative intent for colorectal cancer with neoadjuvant and/or adjuvant chemotherapy
Oral showed no clear difference in disease‐free survival compared with intravenous fluoropyrimidines (moderate certainty).
1 finding from 1 review
Grade ≥ 3 neutropenia/granulocytopenia · Patients treated with palliative intent for inoperable advanced or metastatic colorectal cancer with chemotherapy
Oral may leads to lower grade ≥ 3 neutropenia/granulocytopenia compared with intravenous fluoropyrimidines (low certainty).
1 finding from 1 review
Overall survival · Patients treated with curative intent for colorectal cancer with neoadjuvant and/or adjuvant chemotherapy
Oral showed no clear difference in overall survival compared with intravenous fluoropyrimidines (high certainty).
1 finding from 1 review
Grade ≥ 3 diarrhoea · Patients treated with curative intent for colorectal cancer with neoadjuvant and/or adjuvant chemotherapy
It is very uncertain whether oral changes grade ≥ 3 diarrhoea compared with intravenous fluoropyrimidines (very low certainty).
1 finding from 1 review
Hand‐foot syndrome (grade ≥ 3) · Patients treated with curative intent for colorectal cancer with neoadjuvant and/or adjuvant chemotherapy
Oral may leads to higher grade ≥ 3 hand foot syndrome compared with intravenous fluoropyrimidines (low certainty).
1 finding from 1 review
Grade ≥ 3 neutropenia/granulocytopenia · Patients treated with curative intent for colorectal cancer with neoadjuvant and/or adjuvant chemotherapy
Oral probably leads to lower grade ≥ 3 neutropenia/granulocytopenia compared with intravenous fluoropyrimidines (moderate certainty).
1 finding from 1 review
Progression‐free survival · Patients treated with palliative intent for inoperable advanced or metastatic colorectal cancer with chemotherapy
Oral probably leads to higher progression‐free survival compared with intravenous fluoropyrimidines (moderate certainty).
1 finding from 1 review
Overall survival · Patients treated with palliative intent for inoperable advanced or metastatic colorectal cancer with chemotherapy
Oral showed no clear difference in overall survival compared with intravenous fluoropyrimidines (high certainty).
1 finding from 1 review
Grade ≥ 3 diarrhoea · Patients treated with palliative intent for inoperable advanced or metastatic colorectal cancer with chemotherapy
Oral may leads to higher grade ≥ 3 diarrhoea compared with intravenous fluoropyrimidines (low certainty).
1 finding from 1 review
Hand‐foot syndrome (grade ≥ 3) · Patients treated with palliative intent for inoperable advanced or metastatic colorectal cancer with chemotherapy
Oral probably leads to higher grade ≥ 3 hand foot syndrome compared with intravenous fluoropyrimidines (moderate certainty).
1 finding from 1 review
Death · adults or children with tuberculous meningitis on tuberculosis (TB) chemotherapy
Any corticosteroid leads to lower death compared with control (high certainty).
1 finding from 1 review
Disabling neurological deficit · adults or children with tuberculous meningitis on tuberculosis (TB) chemotherapy
Any corticosteroid showed no clear difference in disabling neurological deficit compared with control (low certainty).
1 finding from 1 review
Bleeding: Number of days on which a significant bleeding event occurred3 · People with a haematological disorder